{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:38:24Z","timestamp":1740184704423,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19198"],"award-info":[{"award-number":["24K19198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0510034"],"award-info":[{"award-number":["JP22ek0510034"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012036","name":"Lotte Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012036","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-024-00680-y","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:52:38Z","timestamp":1732560758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning evaluation of intensified conditioning on haematopoietic stem cell transplantation in adult acute lymphoblastic leukemia patients"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hatsusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-2338","authenticated-orcid":false,"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"680_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(84)92009-9","volume":"2","author":"RP Gale","year":"1984","unstructured":"Gale, R. P. & Champlin, R. E. How does bone-marrow transplantation cure leukaemia? Lancet 2, 28\u201330 (1984).","journal-title":"Lancet"},{"key":"680_CR2","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363, 2091\u20132101 (2010).","journal-title":"N. Engl. J. Med."},{"key":"680_CR3","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/bloodadvances.2022008032","volume":"6","author":"S Nishiwaki","year":"2022","unstructured":"Nishiwaki, S. et al. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Adv. 6, 4558\u20134569 (2022).","journal-title":"Blood Adv."},{"key":"680_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbmt.2008.02.018","volume":"14","author":"A Shigematsu","year":"2008","unstructured":"Shigematsu, A. et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol. Blood Marrow Transplant. 14, 568\u2013575 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"680_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ajh.24933","volume":"93","author":"Y Arai","year":"2018","unstructured":"Arai, Y. et al. Improved prognosis with additional medium-dose VP16 to CY\/TBI in allogeneic transplantation for high risk ALL in adults. Am. J. Hematol. 93, 47\u201357 (2018).","journal-title":"Am. J. Hematol."},{"key":"680_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bjh.14652","volume":"178","author":"Y Arai","year":"2017","unstructured":"Arai, Y. et al. Increased non-relapse mortality due to high-dose cytarabine plus CY\/TBI in BMT\/PBSCT for acute lymphoblastic leukaemia in adults. Br. J. Haematol. 178, 106\u2013111 (2017).","journal-title":"Br. J. Haematol."},{"key":"680_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2015-04-642652","volume":"126","author":"Y Arai","year":"2015","unstructured":"Arai, Y. et al. Efficiency of high-dose cytarabine added to CY\/TBI in cord blood transplantation for myeloid malignancy. Blood 126, 415\u2013422 (2015).","journal-title":"Blood"},{"key":"680_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/hon.3046","volume":"40","author":"M Morita-Fujita","year":"2022","unstructured":"Morita-Fujita, M. et al. Adult patients with Ph+ ALL benefit from conditioning regimen of medium-dose VP16 plus CY\/TBI. Hematol. Oncol. 40, 1041\u20131055 (2022).","journal-title":"Hematol. Oncol."},{"key":"680_CR9","doi-asserted-by":"publisher","first-page":"111538","DOI":"10.1016\/j.jclinepi.2024.111538","volume":"176","author":"K Inoue","year":"2024","unstructured":"Inoue, K. et al. Machine learning approaches to evaluate heterogeneous treatment effects in randomized controlled trials: a scoping review. J. Clin. Epidemiol. 176, 111538 (2024).","journal-title":"J. Clin. Epidemiol."},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1214\/19-BA1195","volume":"15","author":"PR Hahn","year":"2020","unstructured":"Hahn, P. R., Murray, J. S. & Carvalho, C. M. Bayesian regression tree models for causal inference: regularization, confounding, and heterogeneous effects (with discussion). Bayesian Anal. 15, 965\u20131056 (2020).","journal-title":"Bayesian Anal."},{"key":"680_CR11","doi-asserted-by":"publisher","first-page":"e079377","DOI":"10.1136\/bmj-2024-079377","volume":"386","author":"K Inoue","year":"2024","unstructured":"Inoue, K., Athey, S., Baicker, K. & Tsugawa, Y. Heterogeneous effects of Medicaid coverage on cardiovascular risk factors: secondary analysis of randomized controlled trial. BMJ 386, e079377 (2024).","journal-title":"BMJ"},{"key":"680_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/ije\/dyad037","volume":"52","author":"K Inoue","year":"2023","unstructured":"Inoue, K., Athey, S. & Tsugawa, Y. Machine-learning-based high-benefit approach versus conventional high-risk approach in blood pressure management. Int J. Epidemiol. 52, 1243\u20131256 (2023).","journal-title":"Int J. Epidemiol."},{"key":"680_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta, Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J. Hematol. 103, 3\u201310 (2016).","journal-title":"Int J. Hematol."},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda, J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J. Hematol. 103, 11\u201319 (2016).","journal-title":"Int J. Hematol."},{"key":"680_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt, S. et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol. Blood Marrow Transplant. 15, 367\u2013369 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"680_CR16","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson, C. et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 122, 3871\u20133878 (2013).","journal-title":"Blood"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka, P. J., Copelan, E. A. & Klein, J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70, 1382\u20131388 (1987).","journal-title":"Blood"},{"key":"680_CR18","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/bmt.2016.242","volume":"51","author":"Y Arai","year":"2016","unstructured":"Arai, Y. et al. High-dose cytarabine added to CY\/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study. Bone Marrow Transplant. 51, 1636\u20131639 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"680_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"680_CR20","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand, P. et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123, 3664\u20133671 (2014).","journal-title":"Blood"},{"key":"680_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3324\/haematol.2012.076042","volume":"98","author":"Y Atsuta","year":"2013","unstructured":"Atsuta, Y. et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica 98, 814\u2013822 (2013).","journal-title":"Haematologica"},{"key":"680_CR22","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1182\/blood.V99.11.4200","volume":"99","author":"Y Morishima","year":"2002","unstructured":"Morishima, Y. et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99, 4200\u20134206 (2002).","journal-title":"Blood"},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven, D. J. & Buhlmann, P. MissForest-non-parametric missing value imputation for mixed-type data. Bioinformatics 28, 112\u2013118 (2012).","journal-title":"Bioinformatics"},{"key":"680_CR24","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"680_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1214\/09-AOAS285","volume":"4","author":"HA Chipman","year":"2010","unstructured":"Chipman, H. A., George, E. I. & McCulloch, R. E. BART: Bayesian additive regression trees. Ann. Appl. Stat. 4, 266\u2013298 (2010).","journal-title":"Ann. Appl. Stat."},{"key":"680_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman, A. & Rubin, D. B. Inference from iterative simulation using multiple sequences. Stat. Sci. 7, 457\u2013472, 416 (1992).","journal-title":"Stat. Sci."},{"key":"680_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"680_CR28","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912\u20132919 (2005).","journal-title":"Blood"},{"key":"680_CR29","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/cncr.30037","volume":"122","author":"AT Fathi","year":"2016","unstructured":"Fathi, A. T. et al. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer 122, 2379\u20132388 (2016).","journal-title":"Cancer"},{"key":"680_CR30","doi-asserted-by":"publisher","first-page":"E284","DOI":"10.1002\/ajh.24340","volume":"91","author":"T Konuma","year":"2016","unstructured":"Konuma, T. et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am. J. Hematol. 91, E284\u2013E292 (2016).","journal-title":"Am. J. Hematol."},{"key":"680_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132, 393\u2013404 (2018).","journal-title":"Blood"},{"key":"680_CR32","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"680_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740\u2013753 (2016).","journal-title":"N. Engl. J. Med."},{"key":"680_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/hon.3094","volume":"41","author":"T Konuma","year":"2023","unstructured":"Konuma, T. et al. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation. Hematol. Oncol. 41, 147\u2013158 (2023).","journal-title":"Hematol. Oncol."},{"key":"680_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12185-017-2341-y","volume":"107","author":"T Goto","year":"2018","unstructured":"Goto, T. et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J. Hematol. 107, 211\u2013221 (2018).","journal-title":"Int J. Hematol."},{"key":"680_CR36","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1182\/blood-2022-160305","volume":"140","author":"Y Arai","year":"2022","unstructured":"Arai, Y. et al. International collaborative study to compare the prognosis for acute leukemia patients transplanted with intensified myeloablative regimens. Blood 140, 4711\u20134713 (2022).","journal-title":"Blood"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00680-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00680-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T19:03:22Z","timestamp":1732561402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00680-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00680-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"type":"electronic","value":"2730-664X"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}